External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

Key points (machine generated)<ul><li>LianBio is winding down its portfolio of in-licensed drug candidates and returning cash to shareholders.</li><li>The company recently sold exclusive rights to develop and commercialize mavacamten in certain areas of Asia to Bristol Myers Squibb for $350 million.</li><li>LianBio will have approximately $600 million in net cash after the transaction, exceeding its current market capitalization of around $434 million. A strategic review is ongoing, and it is expected that the company will wind down its business and distribute cash to shareholders, potentially leading to a higher share price reflecting its cash holdings.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)LianBio is winding down its portfolio of in-licensed drug candidates and returning cash to shareholders.The company recently sold exclusive rights to develop and commercialize mavacamten in certain areas of Asia to Bristol Myers Squibb for $350 million.LianBio will have approximately $600 million in net cash after the transaction, exceeding its current market capitalization of around $434 million. A strategic review is ongoing, and it is expected that the company will wind down its business and distribute cash to shareholders, potentially leading to a higher share price reflecting its cash holdings.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Lianbio -Ads (LIAN) - Tuesday, Oct 31, 2023

United States

vTv Therapeutics Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the discovery and development of human therapeutics to fill unmet medical needs. vTv Therapeutics serves customers in the United States.

Alaunos Therapeutics Inc. operates as a clinical stage cellular immuno-oncology company. The Company focuses on the treatment of solid tumors through adoptive TCR-T cell therapy. Alaunos Therapeutics serves customers worldwide.

VBI Vaccines, Inc. is a biopharmaceutical company developing technologies to expand vaccine  protection in large underserved markets. The Company's eVLP vaccine platform allows for the  design of enveloped virus-like particle vaccines that closely mimic the target virus.

Oncocyte Corporation operates as a molecular diagnostics company. The Company offers actionable answers at decision points across the cancer care continuum, as well as focuses on improving patient outcomes by accelerating and optimizing diagnosis and treatment. Oncocyte serves clients in the United States.

Cue BioPharma, Inc. operates as a bio-technology company. The Company discovers and develops medicines for cancers and autoimmune diseases. Cue BioPharma focuses on design and clinical development of protein biologics, immunology, and immuno-oncology. Cue BioPharma serves customers in the State of Massachusetts.

Cortexyme, Inc. operates as a biotech company. The Company develops therapeutics and diagnostics for the treatment of alzheimer disease and other neurodegenerative disorders. Cortexyme serves clients in the State of California.

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

Cynata Therapeutics Ltd is involved in regenerative medicine.  The Company is focused on the commercialization of a stem cell platform.

Genematrix Inc. provides diagnostics & therapeutic solution.  The Company's services are based on Restriction Fragment Mass Polymorphism (RFMP) technology and applied to theranostics, prognosis, and molecular diagnosis.

China Regenerative Medicine International Limited is engaged in research and development of bio-medical and healthcare products, and medical techniques, the provision of the production and sales of tissue engineering products and its related by-products, as well as sales and distribution of medical products and equipment.

General Biologicals Corp. produces molecular diagnostic product. The Company's also offer research development, marketing and servicing of products and solutions for hospitals, medical laboratory and blood bank, and research and industry.

Gene Techno Science Co., Ltd. is a biomedicine company that researches and developes drugs. In addition to drug development, the company also supply the pharmaceutical ingredients.

DNA Link Inc. is a biotechnology company specializing in genomic research technology for rapid analysis of whole genomes.  The Company also provides personalized genomic service which analyze individual's genomic sequence to identify his or her susceptibility to genetic diseases and calculate their risk factors.

Daesung Microbiological Labs Co., Ltd. develops and manufactures canine, poultry, swine, and bovine drugs and vaccines.  The Company's products have applications for increasing immunity and preventing epidemic for livestock. Daesung Microbiological Labs also researches microorganism for ocean and soil improvement purposes.

TRANS GENIC INC. develops, produces, and sells specific idiotype bearing antibody (bio reagent).  The Company also develops mutant mice and sells mice' genetic function analysis data.

DR. Chip Biotechnology Inc. develops biochips, nucleic acid extraction kits, rapid hybridization equipment, biotechnology software, as well as provides diagnostic services.

Original BioMedicals Co., Ltd. is a biotechnology company. The Company develops new drugs and creates drug carriers to enhance or repurpose current drugs.

LianBio operates as a biological technology company. The Company develops therapies to treat cardiovascular, oncology, respiratory, ophthalmology and inflammatory disease. LianBio serves customers patients in Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00